| scholarly article | Q13442814 |
| P50 | author | Blake T Aftab | Q99363861 |
| P2093 | author name string | John Prescott | |
| Lillian Lee | |||
| Harvey Wong | |||
| Jean-Francois Martini | |||
| Peiwen Yu | |||
| Ron Aoyama | |||
| Marcia Belvin | |||
| Laurent Vernillet | |||
| Amy Peterson | |||
| Congfen Li | |||
| Yongchang Shi | |||
| Geoffrey Del Rosario | |||
| Klaus P. Hoeflich | |||
| Sanh Tan Lam | |||
| Edna F. Choo | |||
| Joseph A. Ware | |||
| P2860 | cites work | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| Ultrasensitivity in the mitogen-activated protein kinase cascade | Q24597665 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 | ||
| Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data | Q33323274 | ||
| Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. | Q33906093 | ||
| Raf proteins and cancer: B-Raf is identified as a mutational target | Q34648534 | ||
| Diversity of mechanism-based pharmacodynamic models | Q35107049 | ||
| Drug delivery and transport to solid tumors | Q35563687 | ||
| Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development | Q35761426 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Tumor models for efficacy determination | Q36623519 | ||
| B-Raf kinase inhibitors for cancer treatment | Q36875829 | ||
| Novel mitogen-activated protein kinase kinase inhibitors | Q37828536 | ||
| Resistance to MEK Inhibitors: Should We Co-Target Upstream? | Q37859182 | ||
| Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Q37866945 | ||
| Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition | Q39442875 | ||
| Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphory | Q39894543 | ||
| Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy | Q42741853 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
| Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation | Q44485080 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models | Q46670098 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 3090-3099 | |
| P577 | publication date | 2012-04-10 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor | |
| Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor | |||
| P478 | volume | 18 |
| Q33574139 | A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate |
| Q90398825 | Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo |
| Q33767369 | Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model |
| Q38777596 | Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma |
| Q38783292 | Cobimetinib and vemurafenib for the treatment of melanoma |
| Q38603243 | Cobimetinib: First Global Approval |
| Q36396095 | Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro |
| Q38557331 | Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations |
| Q38221107 | Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. |
| Q27024682 | Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research |
| Q34036341 | MEK and the inhibitors: from bench to bedside |
| Q38131383 | MEK inhibition in the treatment of advanced melanoma |
| Q38179145 | MEK1/2 inhibitors in the treatment of gynecologic malignancies. |
| Q45223006 | Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing |
| Q38847931 | Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers |
| Q38207082 | New RAF kinase inhibitors in cancer therapy |
| Q96617442 | Opportunities for quantitative translational modelling in Oncology |
| Q38786230 | Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. |
| Q90292840 | Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors |
| Q34429484 | Phenotypic screening in cancer drug discovery - past, present and future |
| Q41513317 | Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape |
| Q38193520 | Prospects for MEK inhibitors for treating cancer. |
| Q55329667 | Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q38238743 | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer |
| Q38397326 | The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. |
| Q38270129 | The biology and clinical development of MEK inhibitors for cancer |
| Q89746470 | The paradox of cancer genes in non-malignant conditions: implications for precision medicine |
| Q38878056 | Translational value of mouse models in oncology drug development |
| Q39355451 | Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology |
Search more.